Establishment of In Vitro Susceptibility Testing Methodologies and Comparative Activities of Piperacillin in Combination with the Penem β-Lactamase Inhibitor BLI-489

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Antimicrobial Agents and Chemotherapy

• Publication date

  2008-11-10

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1128/AAC.01047-08PMID 19001109PMCID PMC2630610
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Isolation of Imipenem-Resistant Enterobacter Species: Emergence of KPC-2 Carbapenemase, Molecular Characterization, Epidemiology, and Outcomes

  2008cited by this paper
• Novel β-lactam antibiotics and inhibitor combinations

  2008cited by this paper
• Novel beta-lactam antibiotics and inhibitor combinations.

  2008cited by this paper
• Clinically significant carbapenemases: an update

  2008cited by this paper
• Clinical and Economic Impact of Common Multidrug-Resistant Gram-Negative Bacilli

  2007cited by this paper
• Diagnosis and Treatment of Extended-Spectrum and AmpC β-Lactamase–Producing Organisms

  2007influential reference
• Failure of Current Cefepime Breakpoints To Predict Clinical Outcomes of Bacteremia Caused by Gram-Negative Organisms

  2007cited by this paper
• Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : Approved standard

  2006cited by this paper
• Antimicrobial susceptibility pattern comparisons among intensive care unit and general ward Gram-negative isolates from the Meropenem Yearly Susceptibility Test Information Collection Program (USA).

  2006cited by this paper
• Wide geographic spread of diverse acquired AmpC beta-lactamases among Escherichia coli and Klebsiella spp. in the UK and Ireland.

  2006cited by this paper
• Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections.

  2006cited by this paper
• Tigecycline: a review of preclinical and clinical studies of the first-in-class glycylcycline antibiotic.

  2005cited by this paper
• Clinical implications of extended spectrum beta-lactamase (ESBL) producing Klebsiella species and Escherichia coli on cefepime effectiveness.

  2005cited by this paper
• Failure of Cefepime Therapy in Treatment of Klebsiella pneumoniae Bacteremia

  2005cited by this paper
• Novel imidazole substituted 6-methylidene-penems as broad-spectrum beta-lactamase inhibitors.

  2004cited by this paper
• Determining incidence of extended spectrum beta-lactamase producing Enterobacteriaceae, vancomycin-resistant Enterococcus faecium and methicillin-resistant Staphylococcus aureus in 38 centres from 17 countries: the PEARLS study 2001-2002.

  2004cited by this paper
• Structure-activity relationship of 6-methylidene penems bearing tricyclic heterocycles as broad-spectrum beta-lactamase inhibitors: crystallographic structures show unexpected binding of 1,4-thiazepine intermediates.

  2004cited by this paper
• Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 beta-lactamases in New York City.

  2004cited by this paper
• Selection during Cefepime Treatment of a New Cephalosporinase Variant with Extended-Spectrum Resistance to Cefepime in an Enterobacter aerogenes Clinical Isolate

  2004cited by this paper
• In vitro and in vivo activities of novel 6-methylidene penems as beta-lactamase inhibitors.

  2004cited by this paper
• In Vitro and In Vivo Activities of Novel 6-Methylidene Penems as β-Lactamase Inhibitors

  2004cited by this paper
• The impact of beta-lactamases on the development of novel antimicrobial agents.

  2002influential reference
• Plasmid-borne AmpC beta-lactamases.

  2002cited by this paper
• Plasmid-borne AmpC β-lactamases

  2002cited by this paper
• Beta-lactamase-inhibitor combinations in the 21st century: current agents and new developments.

  2001cited by this paper
• Extended-Spectrum β-Lactamases in the 21st Century: Characterization, Epidemiology, and Detection of This Important Resistance Threat

  2001cited by this paper
• Extension of resistance to cefepime and cefpirome associated to a six amino acid deletion in the H-10 helix of the cephalosporinase of an Enterobacter cloacae clinical isolate.

  2001cited by this paper
• Performance standards for antimicrobial susceptibility testing

  2001cited by this paper
• β-Lactamase-inhibitor combinations in the 21st century: current agents and new developments

  2001cited by this paper
• Evolution and epidemiology of extended-spectrum beta-lactamases (ESBLs) and ESBL-producing microorganisms.

  2001cited by this paper
• Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard

  2000cited by this paper
• Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard

  2000cited by this paper
• Characterization of expanded-spectrum cephalosporin resistance in E. coli isolates associated with bovine calf diarrhoeal disease.

  1999influential reference
• CTX-M-5, a Novel Cefotaxime-Hydrolyzing β-Lactamase from an Outbreak of Salmonella typhimuriumin Latvia

  1998cited by this paper
• Resistant penicillin-binding proteins

  1998cited by this paper
• Beta-lactamase inhibitors: agents to overcome bacterial resistance.

  1998influential reference
• Ceftazidime-Resistant Klebsiella pneumoniae and Escherichia coli Isolates Producing TEM-10 and TEM-43 β-Lactamases from St. Louis, Missouri

  1998influential reference
• Evolution of extended-spectrum beta-lactam resistance (SHV-8) in a strain of Escherichia coli during multiple episodes of bacteremia

  1997influential reference
• Fixed or variable concentrations of βlactamase inhibitors in in-vitro tests?

  1996cited by this paper
• TEM-28 from an Escherichia coli clinical isolate is a member of the His-164 family of TEM-1 extended-spectrum beta-lactamases

  1996cited by this paper
• In vitro activity of piperacillin/tazobactam against isolates from patients enrolled in clinical trials.

  1996cited by this paper
• Fixed or variable concentrations of beta-lactamase inhibitors in in-vitro tests?

  1996cited by this paper
• Development of test panel of beta-lactamases expressed in a common Escherichia coli host background for evaluation of new beta-lactam antibiotics

  1995cited by this paper
• A functional classification scheme for beta-lactamases and its correlation with molecular structure

  1995cited by this paper
• SHV-7, a novel cefotaxime-hydrolyzing beta-lactamase, identified in Escherichia coli isolates from hospitalized nursing home patients

  1995cited by this paper
• Suggested modifications for disk diffusion susceptibility testing criteria for levofloxacin and sparfloxacin following tests with a predictor panel of ciprofloxacin-resistant clinical isolates

  1995cited by this paper
• Identification of TEM-26 beta-lactamase responsible for a major outbreak of ceftazidime-resistant Klebsiella pneumoniae

  1994cited by this paper
• Multiply resistant Klebsiella pneumoniae strains from two Chicago hospitals: identification of the extended-spectrum TEM-12 and TEM-10 ceftazidime-hydrolyzing beta-lactamases in a single isolate

  1994cited by this paper
• Use of a predictor panel to evaluate susceptibility testing methods for ampicillin-sulbactam

  1993cited by this paper
• Use of a predictor panel to evaluate susceptibility test methods proposed for piperacillin-tazobactam

  1993cited by this paper
• Genetically diverse ceftazidime-resistant isolates from a single center: biochemical and genetic characterization of TEM-10 beta-lactamases encoded by different nucleotide sequences

  1993cited by this paper
• Problems with detection of beta-lactam resistance among nonfastidious gram-negative bacilli.

  1993cited by this paper
• Use of a predictor panel for development of a new disk for diffusion tests with cefoperazone-sulbactam

  1992cited by this paper
• Novel plasmid-mediated beta-lactamase (MIR-1) conferring resistance to oxyimino- and alpha-methoxy beta-lactams in clinical isolates of Klebsiella pneumoniae

  1990cited by this paper
• Cloning and sequencing of the class B beta-lactamase gene (ccrA) from Bacteroides fragilis TAL3636

  1990cited by this paper
• Studies to optimize the in vitro testing of piperacillin combined with tazobactam (YTR 830).

  1989cited by this paper

• Synergistic effects of ceftriaxone combined with BLI-489 against NDM-producing Klebsiella pneumoniae

  2026cites this paper
• Recent Developments in Penem Antibiotics: Structural and Therapeutic Perspectives

  2025cites this paper
• Synergistic effect of the novel β-lactamase inhibitor BLI-489 combined with imipenem or meropenem against diverse carbapenemase-producing carbapenem-resistant Enterobacterales.

  2022cites this paper
• In vitro and in vivo activities of imipenem combined with BLI-489 against class D β-lactamase-producing Acinetobacter baumannii.

  2020cites this paper
• Preserving the Dwindling β-lactams-Based Empiric Therapy Options for Gram-Negative Infections in Challenging Resistance Scenario: Lessons Learned and Way Forward

  2019cites this paper
• A Systematic Approach to the Selection of the Appropriate Avibactam Concentration for Use with Ceftazidime in Broth Microdilution Susceptibility Testing

  2018cites this paper
• Relationship between &bgr;‐lactamase production and resistance phenotype in Klebsiella pneumoniae strains

  2017cites this paper
• A structural, epidemiological & genetic overview of Klebsiella pneumoniae carbapenemases (KPCs)

  2016cites this paper
• Multidrug-resistant Gram-negative bacterial infections: are you ready for the challenge?

  2014cites this paper
• New antibacterial agents: patent applications published in 2011.

  2014cites this paper
• Alkylidene Oxapenem β-Lactamase Inhibitors Revisited: Potent Broad Spectrum Activity but New Stability Challenges.

  2014cites this paper
• The threat of carbapenem-resistant Enterobacteriaceae in Lebanon: an update on the regional and local epidemiology.

  2012cites this paper
• Carbapenemases in Klebsiella pneumoniae and Other Enterobacteriaceae: an Evolving Crisis of Global Dimensions

  2012cites this paper
• Crisis of Global Dimensions and Other Enterobacteriaceae: an Evolving Carbapenemases in Klebsiella pneumoniae

  2012cites this paper
• Substitutions at Position 105 in SHV Family β-Lactamases Decrease Catalytic Efficiency and Cause Inhibitor Resistance

  2012influential citation
• Novel antimicrobial agents against multi-drug-resistant gram-negative bacteria: an overview.

  2012cites this paper
• Current trends in β-lactam based β-lactamases inhibitors.

  2011cites this paper
• New β-lactam antibiotics and β-lactamase inhibitors

  2010cites this paper
• Current Challenges in Antimicrobial Chemotherapy

  2010cites this paper
• β-Lactam Antibiotics

  2010cites this paper
• Three Decades of β-Lactamase Inhibitors

  2010influential citation
• Newer antibacterial agents and their potential role in cystic fibrosis pulmonary exacerbation management.

  2010cites this paper
• Resistance development profiling of piperacillin in combination with the novel {beta}-lactamase inhibitor BLI-489.

  2010cites this paper